Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
APN401 was well tolerated in 17 patients with advanced solid tumors, with no dose-limiting toxicities. invIOs selected 4.5×10⁷ PBMCs/kg as the recommended Phase 2 dose; disease stabilization occurred in 5 of 10 RECIST-evaluable patients.
EQS-News: invIOs GmbH / Key word(s): Scientific publication invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal 15.10.2026 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. ═══════════════════════════════════════════════